These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 32847988)
1. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity. Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988 [TBL] [Abstract][Full Text] [Related]
2. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621 [TBL] [Abstract][Full Text] [Related]
3. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029 [TBL] [Abstract][Full Text] [Related]
4. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma. Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869 [TBL] [Abstract][Full Text] [Related]
5. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176 [TBL] [Abstract][Full Text] [Related]
7. Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress. Zhu L; Gao H; Huang S; Cao T; Zhai X; Hu J; Wang T; Dong J; Liu Z; Chen J; Liu J; Zhang Z; Zhou Q Gene; 2023 Jan; 851():146962. PubMed ID: 36272651 [TBL] [Abstract][Full Text] [Related]
8. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097 [TBL] [Abstract][Full Text] [Related]
9. Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8 Kosaka A; Yajima Y; Yasuda S; Komatsuda H; Nagato T; Oikawa K; Kobayashi H; Ohkuri T Int J Cancer; 2023 Apr; 152(8):1685-1697. PubMed ID: 36495276 [TBL] [Abstract][Full Text] [Related]
10. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188 [TBL] [Abstract][Full Text] [Related]
11. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380 [TBL] [Abstract][Full Text] [Related]
12. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer. Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334 [TBL] [Abstract][Full Text] [Related]
13. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989 [TBL] [Abstract][Full Text] [Related]
14. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461 [TBL] [Abstract][Full Text] [Related]
15. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context. Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R Front Oncol; 2023; 13():1249524. PubMed ID: 37655095 [TBL] [Abstract][Full Text] [Related]
17. Activation of the STING adaptor attenuates experimental autoimmune encephalitis. Lemos H; Huang L; Chandler PR; Mohamed E; Souza GR; Li L; Pacholczyk G; Barber GN; Hayakawa Y; Munn DH; Mellor AL J Immunol; 2014 Jun; 192(12):5571-8. PubMed ID: 24799564 [TBL] [Abstract][Full Text] [Related]
18. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
19. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690 [TBL] [Abstract][Full Text] [Related]